eligibility_summary
Eligible: Individuals with B-cell non-Hodgkin lymphoma (B-NHL) that is relapsed or refractory and who will be treated with glofitamab. Exclude: participants currently in or planning to join another interventional clinical trial, or anyone deemed unsuitable by the investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Glofitamab, a T‑cell–redirecting bispecific monoclonal antibody drug used with physician‑selected salvage therapy. Mechanism: binds CD20 on B cells and CD3 on T cells (2:1 CD20:CD3 format), creating an immune synapse that activates cytotoxic T cells to kill CD20+ malignant B cells. Targets/cells/pathways: CD20+ B‑cell lymphoma cells, CD3/T‑cell receptor signaling on T cells, T‑cell activation, immune‑synapse formation, cytokine‑mediated cytotoxicity and apoptosis of B cells. Study: prospective, observational in Chinese adults with relapsed/refractory B‑NHL.